AI in Urology: Reshaping Patient Care
Urology Times
Urology news resource spotlighting key advances in surgical and non-surgical treatments as well as practice management.
Welcome back to Urology Times' LinkedIn newsletter, Urologically Speaking! In this issue, we'll be highlighting our most recent coverage of news and insights on the transformative potential of artificial intelligence (AI) in urology.
Take a look through some of the top stories below!
FDA grants de novo authorization to ArteraAI Prostate
On August 13, 2025, Artera announced that the FDA had granted de novo authorization to ArteraAI Prostate, an AI-powered risk stratification tool for patients with non-metastatic prostate cancer.
The test has been validated using data from several phase 3 trials to predict therapy benefit and prognosticate long-term outcomes, making it the first AI platform of its kind for patients with non-metastatic prostate cancer.
AI and prostate cancer: Balancing hope and caution
In a recent interview with Urology Times, Christopher Weight , MD, MS, of Cleveland Clinic shared his thoughts on the current state and directions of AI and prostate cancer. Although optimistic about AI’s potential to improve patient selection and reduce overtreatment, he stressed the importance of rigorous validation to ensure accuracy, reproducibility, and equitable application.
AI tool can detect prostate cancer missed by pathologists
An AI model has demonstrated the ability to predict a future diagnosis of clinically significant prostate cancer based on initial benign prostate biopsies, according to recent data published in Nature. Overall, the model achieved an AUC of 0.82 at the patient level, and identified patterns such as stromal collagen and altered glandular epithelial cells in those who did develop prostate cancer.
Experts discuss the transformative potential of AI for BPH
Urology is a technology-driven field, making it an ideal environment for the integration of AI into routine clinical practice.
In a recent interview with Urology Times, Giovanni Cacciamani MD, FEBU ; Liam Murad ; and Kevin Zorn , MD, FRCSC, FACS, discuss the ways in which AI could transform patient care and improve physician workflows, particularly for benign prostatic hyperplasia.
Justin Dubin, MD, on the use of AI in the male infertility space
Justin Dubin M.D. , a men’s health expert at Memorial Healthcare System in Florida, recently sat down with Urology Times to explain how AI is currently being used in the male infertility space. Specifically, he touched on the technology’s current applications in performing semen analyses as well as in predicting outcomes with microsurgical testicular sperm extraction in patients with azoospermia.